2025-10-23 - Analysis Report
Okay, here's the analysis of Eli Lilly and Co. (LLY), incorporating all the provided data points. The report is in English, starts with key numbers, includes analysis, and follows your requested structure.

***

## Eli Lilly and Co. (LLY) Stock Analysis

**Ticker:** LLY
**Company Overview:** Eli Lilly and Company is a global pharmaceutical company that discovers, develops, manufactures, and markets pharmaceutical products.

**1. Performance vs. S&P 500 (VOO):**

*   **LLY Cumulative Return:** 206.85%
*   **VOO Cumulative Return:** 99.09%
*   **Absolute Divergence:** 107.76%
*   **Divergence Range:** Max: 248.5, Min: -33.6
*   **Relative Divergence:** 50.8

**Analysis:** LLY has significantly outperformed the S&P 500 (VOO) over the observed period. The relative divergence of 50.8 indicates that LLY's outperformance is positioned around the midpoint of its historical divergence range.

**Alpha, Beta Analysis:**

| Year       | CAGR    | MDD    | Alpha   | Beta  | Cap(B) |
|------------|---------|--------|---------|-------|--------|
| 2015-2017  | 11.0%   | 76.1%  | -17.0%  | -0.0  | 77.2   |
| 2016-2018  | 39.0%   | 68.9%  | 24.0%   | -0.0  | 105.8  |
| 2017-2019  | 41.0%   | 68.9%  | 19.0%   | 0.4   | 120.2  |
| 2018-2020  | 34.0%   | 79.8%  | 10.0%   | 0.4   | 154.4  |
| 2019-2021  | 53.0%   | 79.8%  | 7.0%    | 0.5   | 252.6  |
| 2020-2022  | 64.0%   | 79.8%  | 65.0%   | 0.4   | 334.6  |
| 2021-2023  | 125.0%  | 78.9%  | 124.0%  | 0.2   | 533.1  |
| 2022-2024  | 134.0%  | 81.2%  | 113.0%  | 0.2   | 706.1  |
| 2023-2025  | 98.0%   | 83.5%  | 35.0%   | 0.2   | 731.3  |

**Analysis:**

*   **CAGR:** Consistently high CAGR values demonstrate strong growth, particularly in recent years (2021-2024).
*   **MDD:** High MDD values suggest significant volatility and potential drawdowns.
*   **Alpha:**  The high and positive Alpha values, especially in recent periods (2020-2024), indicate that LLY's returns are largely independent of market movements (S&P 500).
*   **Beta:** Low Beta values suggest that LLY is less sensitive to market fluctuations than the S&P 500.
*   **Market Cap:**  The Market Cap has increased significantly over time, reflecting the company's growth.

**2. Recent Price Action:**

*   **Current Price:** 799.57
*   **Last Market Data:** Price: 812.43, Previous Close: 799.57, Change: 1.61%
*   **5-day Moving Average:** 811.46
*   **20-day Moving Average:** 802.42
*   **60-day Moving Average:** 751.42

**Analysis:** The stock price is currently below the 5-day and 20-day moving averages, suggesting a potential short-term pullback. However, it's significantly above the 60-day moving average, indicating a strong longer-term uptrend. The 1.61% change in the last market suggests some positive momentum.

**3. Technical Indicators:**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 39.33 (Approaching oversold territory)
*   **PPO:** -0.60 (Below zero, suggesting potential short-term weakness)
*   **Hybrid Signal:** cash_0%_Buy 100% of cash (1 shares - Very Safe - MRI:0.90) Monthly invest 0.8% of total investment ($1,000.00) (Cash Ratio: 0% on 2025-10-01)
*   **Recent (20-day) Relative Divergence Change:** -5.8 (Negative, suggesting short-term underperformance compared to the S&P 500)
*   **Expected Return:** 129.4% (Long-term, relative to S&P 500)

**Analysis:** The MRI indicates a high investment recommendation. The RSI is approaching oversold territory, which could signal a potential buying opportunity. The negative PPO and the declining relative divergence suggest short-term weakness. However, the very strong expected return indicates significant long-term upside potential.

**4. Recent News & Significant Events:**

*   **Guardant Health (GH) FDA Approval for Lilly's Inluriyo Blood Test:** Positive news, likely to support revenue growth for LLY.
*   **NVO Stock Falls Amid Governance Shift:** While not directly related to LLY, events in the pharmaceutical sector can impact overall investor sentiment.
*   **3 Things Investors Need to Know Ahead of Eli Lilly's Q3 Earnings Report:**  Suggests increased investor focus and potential volatility around the upcoming earnings release. Investors are likely awaiting clarity on pipeline progress and financial performance.
*   **US pharma price probe raises threat of new drug tariffs:** This headline is concerning as potential drug pricing regulations and tariffs could negatively impact profitability.
*   **Eli Lilly and Company (LLY): A Bull Case Theory:** Reinforces positive long-term outlook.
*   **Investor seizes Novo Nordisk board in weight-loss drug battle:** This could cause concern regarding the competition with similar weight-loss drugs.

**4-2. Analyst Opinions:**

*   **Consensus:** Buy
*   **Mean Rating:** 1.76 (~Buy)
*   **Opinions:** 27
*   **Target Price (avg/high/low):** 894.33 / 1190.00 / 650.00

**Analysis:** The strong buy consensus and high average target price suggest that analysts are generally optimistic about LLY's future prospects.

**5. Recent Earnings Analysis:**

| 날짜         | EPS  | 매출      |
|--------------|------|-----------|
| 2025-08-07   | 6.3  | 15.56 B$  |
| 2025-05-01   | 3.07 | 12.73 B$  |
| 2024-10-30   | 1.08 | 11.44 B$  |
| 2024-08-08   | 3.29 | 11.30 B$  |
| 2025-08-07   | 3.29 | 11.30 B$  |

**Analysis:**  The EPS and revenue figures generally show growth, with a particularly strong EPS figure in the most recent quarter (2025-08-07). However, there seems to be duplicate data, which impacts the analysis.

**6. Financial Information:**

**Revenue and Profitability:**

| Quarter    | Revenue   | Profit Margin |
|------------|-----------|---------------|
| 2025-06-30 | $15.56B   | 84.27%        |
| 2025-03-31 | $12.73B   | 82.53%        |
| 2024-12-31 | $13.53B   | 82.24%        |
| 2024-09-30 | $11.44B   | 81.02%        |
| 2024-06-30 | $11.30B   | 80.80%        |

**Capital and Profitability:**

| Quarter    | Equity    | ROE       |
|------------|-----------|-----------|
| 2025-06-30 | $18.27B   | 30.98%    |
| 2025-03-31 | $15.76B   | 17.50%    |
| 2024-12-31 | $14.19B   | 31.07%    |
| 2024-09-30 | $14.24B   | 6.81%     |
| 2024-06-30 | $13.56B   | 21.88%    |

**Analysis:**

*   **Revenue:** Increasing revenue trend is evident.
*   **Profit Margin:**  Very high and stable profit margins, indicating strong pricing power and efficient operations.
*   **Equity:** Increasing equity suggests healthy capital accumulation.
*   **ROE:**  Generally high ROE, indicating efficient use of shareholder equity to generate profits. There is fluctuation, suggesting possible impacts of external factors.

**7. Overall Summary:**

Eli Lilly and Company (LLY) demonstrates very strong financial performance, high growth potential, and significant outperformance relative to the S&P 500. The high profit margins, increasing revenue, and strong ROE highlight the company's efficiency and profitability.

**Key Positives:**

*   **Strong Financials:** High revenue growth, excellent profit margins, and increasing equity.
*   **Outperformance:** Significant historical outperformance compared to the S&P 500.
*   **Positive Analyst Sentiment:**  Strong buy consensus and high price targets.
*   **Pipeline Progress:** Recent news regarding FDA approval for a blood test related to LLY's drug is a positive catalyst.
*   **High Expected Return:** Significant long-term upside potential.
*   **High Investment Recommended:** MRI of 0.9.

**Potential Risks/Concerns:**

*   **High MDD:** Significant past volatility, meaning there is potential for future drawdowns.
*   **Short-Term Weakness:** Recent price action and technical indicators suggest potential short-term pullback.
*   **Pharmaceutical Pricing Pressures:**  The US pharma price probe raises concerns about potential future regulations and tariffs.
*   **Competition:** Novo Nordisk competition, particularly in the weight-loss drug sector, requires monitoring.
*  **Duplicate data**: There seems to be duplicated data in the Earnings Analysis, which needs to be checked for correctness.

**Overall Recommendation:**

LLY appears to be a compelling investment opportunity for long-term investors, particularly those seeking growth and willing to tolerate some volatility. The company's strong financials, positive analyst sentiment, and pipeline progress are all encouraging factors. However, investors should be aware of the potential risks related to pharmaceutical pricing pressures and market volatility. Due to the duplicated data, further analysis is needed to verify all the information.
